Torii Pharmaceutical Co., Ltd - TRXPF

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products. The company’s products include REMITCH, an agent used for the treatment of pruritus in hemodialysis patients; Truvada, an antiretroviral agent used for the treatment of human immunodeficiency virus (HIV); ANTEBATE, an agent used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; Riona, a therapeutic agent for hyperphosphatemia; and Stribild combination tablets for the treatment HIV. It also provides FUTHAN for injection, an anticoagulant drug used during hemodiafiltration; KAYEXALATE, a therapeutic agent for hyperkalemia treatment; and URINORM, an uricosuric agent. In addition, the company offers LOCOID, an agent used for the treatment of the inflammatory manifestations of dermatosis; and ZEFNART, a topical antifungal agent. Further, it provides CEDARTOLEN, a sublingual immunotherapy drug; MITICURE, an allergen immunotherapy tablet; Genvoya combination tablets for the treatment of HIV-1 infection; Descovy, an antiviral agent for HIV; Bio-Three viable bacterial preparations; URINORM, a renal diseases and hemodialysis uricosuric agent; and Magsent used for the treatment for premature labor Eclampsia-suppressing. Torii Pharmaceutical Co., Ltd. has collaboration with Japan Tobacco Inc. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.